Preclinical News and Research

RSS

Indiana University Study Identifies New Pathway to Combat Leukemia

Indiana University School of Medicine cancer researchers have identified a potential way to use existing, accessible drugs to combat juvenile myelomonocytic leukemia (JMML) by targeting a specific inflammatory pathway.

19 Jun 2026

Advanced Bladder Cancer Spatial Mapping Identifies Diverse Cellular Tumor States

Researchers at The University of Texas MD Anderson Cancer Center have developed a spatial map of muscle-invasive bladder cancer, revealing how tumor cell states, immune environments and therapeutic vulnerabilities are organized within tumors.

19 Jun 2026

Collaborative Research Discovers New Treatments for Alzheimer' Disease

A new multimillion-dollar project will bring together researchers from the Indiana University School of Medicine and the IU Luddy School of Informatics, Computing, and Engineering as they work to solve one of medical science's greatest needs: Identifying new treatments for Alzheimer's disease and related dementias.

16 Jun 2026

New Gene-Editing Strategy Ensures Quality Control in Stem Cell Therapies

A team of researchers led by Luigi Naldini at the San Raffaele Telethon Institute for Gene Therapy (SR-Tiget) has developed a new strategy to significantly improve the precision and safety of CRISPR-Cas9 gene editing.

3 Jun 2026

Bispecific Antibodies Target Tumors While Sparing Healthy Tissue

A new generation of bispecific antibodies effectively targets cancer cells, minimizing toxicity and enhancing treatment precision in preclinical studies.

3 Jun 2026

Introducing Evosep Proteomics to Standardize and Scale Proteomics for Research and Drug Development

Evosep announces the launch of Evosep Proteomics, an ecosystem designed to standardize and scale LC-MS-based proteomics for research and pharmaceutical drug development.

From Evosep 2 Jun 2026

Nanoparticles Boost Delivery of Lung Cancer Drugs 30-Fold

Lung cancer remains one of the world’s deadliest cancers, yet despite decades of effort to develop new drugs, many fail because they don’t stay in the body long enough to be effective or because they damage healthy organs.

1 Jun 2026

MRM Health Rewarded a € 2.6 M VLAIO Research Grant to Accelerate the Development of Novel Therapeutics that Redefine the Treatment of Immune-Mediated Inflammatory Diseases

MRM Health, a clinical-stage biopharmaceutical company developing therapeutics for immune-mediated diseases, which unlock the power of the microbiome to restore immune balance, today announced that it has been awarded a research grant of € 2.6M from Flanders Innovation and Entrepreneurship (VLAIO), a government organization with the goal to stimulate economic development in Flanders, Belgium.

29 May 2026

Macrophage Placement Determines if Tumors Thrive or Regress

Cancer tumors are surrounded by immune cells, but not all of those cells help the body fight back. Some support anti-cancer immunity, while others can unexpectedly help tumors survive.

27 May 2026

Ovarian Cancer Fluid Helps Tumors Evade Cell Death

Ascites in ovarian cancer rewires tumor metabolism, protecting cells from ferroptosis and promoting metastasis, revealing potential therapeutic targets.

27 May 2026

Researchers Link Brain Extracellular Matrix Deterioration to Postmenopausal Memory Loss

A largely overlooked space between cells in women's brains may hold the key to understanding memory loss tied to estrogen decline after menopause, reports a new preclinical Northwestern Medicine study.

26 May 2026

Researchers Reverse Immune Cell Dysfunction by Degrading Key Gene Regulatory Proteins

Researchers at the Icahn School of Medicine at Mount Sinai, Bristol Myers Squibb, and the University of Oxford have discovered a way to give worn-out immune cells a second wind in the fight against multiple myeloma.

20 May 2026

Study Reveals New Biological Pathway for TNF-Resistant Crohn’s Disease

Mayo Clinic researchers have identified an immune-regulating molecule that may help explain why some patients with inflammatory bowel disease (IBD), including Crohn's disease and ulcerative colitis, do not respond to commonly used therapies.

14 May 2026

AI Designs New Antibiotics That Reduce MRSA Infections In Mice

SyntheMol-RL integrates reinforcement learning for antibiotic design, producing synthesizable candidates that show efficacy against MRSA in preclinical models.

5 May 2026

Metabolic Pathway Loss Makes Cancer Cells Vulnerable to PARP Drugs

Loss of an enzyme necessary for a process called lipoylation disrupts the way cancer cells copy their DNA, increasing their vulnerability to a class of anticancer drugs known as PARP inhibitors, a study led by UT Southwestern Medical Center researchers shows.

5 May 2026

Intermediate PRRX1 Levels Drive Breast Cancer Metastasis Risk

The study identifies PRRX1 as a critical factor in breast cancer metastasis, highlighting its potential as a biomarker for predicting aggressive disease.

29 Apr 2026

Researchers Develop 3D Organoids that Reflect the Complexity of Brain Tumors

Efforts to identify and evaluate next-generation therapeutics for pediatric brain tumors are easily stymied by the quality and availability of laboratory models for research. To address this issue, scientists at St. Jude Children's Research Hospital developed patient-derived tumor organoids and tumor organoid xenografts that accurately reflect the biologic underpinnings of embryonal brain tumors.

16 Apr 2026

New Experimental System Mimics Low-Grade Pediatric Glioma in 3D

A three-dimensional experimental system has been developed to study the response to drugs in low-grade glioma, a tumor of the central nervous system that often occurs in children.

10 Apr 2026

Semen-Derived Exosomes Eye Drops to Treat Retinoblastoma

Innovative eye drops using semen-derived exosomes target retinoblastoma, improving therapeutic delivery and preserving ocular function in preclinical models.

8 Apr 2026

New Mouse Model Reveals Viral Path to Liver Cancer

Liver cancer is one of the world's deadliest cancers, and most cases are linked to chronic viral hepatitis. Yet scientists have lacked an animal model that faithfully recapitulates how the disease unfolds in people, from initial infection with a virus to liver inflammation, scarring, and cancer.

7 Apr 2026